Liposomes Patents (Class 424/450)
-
Patent number: 11931459Abstract: In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.Type: GrantFiled: March 17, 2022Date of Patent: March 19, 2024Assignee: Pacira Pharmaceuticals, Inc.Inventor: Roy Winston
-
Patent number: 11925706Abstract: Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.Type: GrantFiled: May 30, 2023Date of Patent: March 12, 2024Assignee: Pacira Pharmaceuticals, Inc.Inventors: Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Kathleen D. A. Los
-
Patent number: 11918565Abstract: Provided herein are methods of administering to a peroneal and a tibial nerve of a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of a patient; (b) inserting the injection needle into the patient at the entry point; (c) administering to a sciatic nerve of the patient via the injection needle saline and a pharmaceutical composition; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome.Type: GrantFiled: February 2, 2023Date of Patent: March 5, 2024Assignee: Pacira Pharmaceuticals, Inc.Inventors: Roy Winston, Mary DiGiorgi
-
Patent number: 11911458Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.Type: GrantFiled: July 7, 2017Date of Patent: February 27, 2024Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Gary Mansfield
-
Patent number: 11904052Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.Type: GrantFiled: May 20, 2022Date of Patent: February 20, 2024Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Jeffrey P. Bechard, Wayne J. Wallis
-
Patent number: 11904019Abstract: The present invention provides a bilirubin nanoparticle formed by the self-assembly of bilirubin and a composite comprising a hydrophilic polymer, a use thereof, and a preparation method therefor. The bilirubin nanoparticle according to the present invention can release a drug enclosed therein to the outside by being collapsed by light or active oxygen stimulation. The bilirubin nanoparticle according to the present invention exhibits antioxidant, antiangiogenic, anticancer, and anti-inflammatory activities.Type: GrantFiled: December 26, 2014Date of Patent: February 20, 2024Assignee: BILIX CO., LTD.Inventors: Sang Yong Jon, Yong Hyun Lee
-
Patent number: 11903986Abstract: In preferred the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.Type: GrantFiled: August 18, 2017Date of Patent: February 20, 2024Assignee: Akrivista LLCInventors: Scott Whitcup, Orest Olejnik, Michael Garst
-
Patent number: 11896712Abstract: The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.Type: GrantFiled: September 11, 2020Date of Patent: February 13, 2024Assignee: Versantis AGInventors: Jean-Christophe Leroux, Vincent Forster
-
Patent number: 11896677Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.Type: GrantFiled: July 24, 2023Date of Patent: February 13, 2024Assignee: HDT Bio Corp.Inventors: Amit Khandhar, Steven Reed, Malcolm Duthie, Jesse Erasmus, Darrick Carter, Bryan J. Berube
-
Patent number: 11890352Abstract: The present invention provides compositions and methods to treat cancer.Type: GrantFiled: February 27, 2019Date of Patent: February 6, 2024Assignee: University of Virginia Patent FoundationInventors: Kimberly A. Kelly, Siva Sai Krishna Dasa
-
Patent number: 11872257Abstract: The present invention relates to Saccharomyces boulardii yeast cells, for use in the prevention or treatment of mood disorders, in a person.Type: GrantFiled: August 10, 2018Date of Patent: January 16, 2024Assignee: BIOCODEXInventors: Emmanuelle Simon O'Brien, Marc Verleye, Marie-Emmanuelle Le Guern
-
Patent number: 11866475Abstract: The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.Type: GrantFiled: June 6, 2017Date of Patent: January 9, 2024Assignee: ModernaTX, Inc.Inventors: Leif Karlsson Parinder, Regina Desirée Fritsche Danielson, Kenny Mikael Hansson, Li Ming Gan, Jonathan Clarke, Ann-Charlotte Eva Egnell, Kenneth Randall Chien
-
Patent number: 11857680Abstract: The present invention relates to a pharmaceutical liposomal composition comprising of about 0.8% w/w to about 1% w/w of docetaxel, about 30% w/w to about 38% w/w of Soya Phosphatidyl Choline, about 0.2% w/w to about 0.8% w/w of Sodium Cholesteryl Sulfate, about 61% w/w to about 68% w/w of Sucrose and a pH adjusting agent, wherein the pH of liposomal composition is less than 3.5 and the process for preparation thereof.Type: GrantFiled: October 19, 2020Date of Patent: January 2, 2024Assignee: SHILPA MEDICARE LIMITEDInventors: Kiran K Jadhav, Prashanth S, Shivakumar Pradeep, Sreenivasa Reddy
-
Patent number: 11856944Abstract: An ex-vivo lung solution for machine perfusion of donor lungs on OCS. The solution may be mixed with whole blood or packed red blood cells to form the OCS lung perfusion solution.Type: GrantFiled: July 20, 2022Date of Patent: January 2, 2024Assignee: TRANSMEDICS, INC.Inventors: Waleed H. Hassanein, Ihab Abdel Fattah, Paul Lezberg, Tamer I. Khayal, Robert Havener, Anas Abdelazim
-
Patent number: 11844820Abstract: The present invention provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analogue or derivative thereof and (ii) a penetration enhancer, and optionally including tannic acid, or an analogue or derivative thereof. The present invention also provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analogue or derivative thereof, and (ii) tannic acid, or an analogue or derivative thereof, optionally including a penetration enhancer. Also provided are kits and methods of prophylactic or therapeutic treatment of inflammatory and/or degenerative conditions using the combination of active ingredients as herein described.Type: GrantFiled: April 29, 2019Date of Patent: December 19, 2023Assignee: ARTHRITIS RELIEF PLUS LTD.Inventors: Larry McKay, Kanu Patel, Robert John Capon
-
Patent number: 11833255Abstract: Provided is a nanoparticle comprising a pH-responsive polymer, a pH-insensitive polymer and a payload molecule. The nanoparticle can act as a system for delivery of the payload that releases the payload in a pH sensitive manner.Type: GrantFiled: October 7, 2016Date of Patent: December 5, 2023Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute Of TechnologyInventors: Sunandini Chopra, Rohit Karnik, Amy Wang, Omid C. Farokhzad, Xue-Qing Zhang
-
Patent number: 11833196Abstract: The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).Type: GrantFiled: October 14, 2021Date of Patent: December 5, 2023Assignee: The Regents of the University of MichiganInventors: James J. Moon, Rui Kuai, Anna A. Schwendeman, Jutaek Nam
-
Patent number: 11801223Abstract: The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.Type: GrantFiled: December 29, 2014Date of Patent: October 31, 2023Assignee: ACCESS TO ADVANCED HEALTH INSTITUTEInventors: Christopher B. Fox, Thomas Vedvick, Lucien Barnes V., Ryan M. Kramer, Steven G. Reed
-
Patent number: 11793873Abstract: The present invention relates to the construction of, and immunization with viral vaccines. In particular, bivalent vaccines that are capable of providing simultaneous virus infection protection for two or more different viruses. Furthermore, the bivalent vaccines contemplated herein are contemplated as being effective in a neonatal mammal. One such bivalent viral vaccine comprises two antigenic epitopes against the dengue viruses and at least one antigenic epitope against hepatitis B virus. Immunization cross-reactivity may also provide infection protection against other viruses as well.Type: GrantFiled: May 1, 2018Date of Patent: October 24, 2023Assignee: UNIVERSITY OF MASSACHUSETTSInventor: Daniel H. Libraty
-
Patent number: 11786468Abstract: The invention provides a (drug-containing) lipid nanoparticle with: (i) at least one phospholipid; (ii) at least one lysolipid; and (iii) at least one phospholipid comprising a hydrophilic polymer; and (iv) at least one structural lipid of formula (I) which has the following general structure: wherein R and R? are long hydrocarbyl hydrophobic chains, Y is a linker element, and PHG is a polar head group described as large according to its van der Waals radius, and which is different from the phospholipid (i). The lipid nanoparticle can release a drug (or API) from within the lipid nanoparticle as a result of focused ultrasound (FUS) applied continuously, at least twice, to a desired part of the body to induce hyperthermia (an increase in temperature). FUS is applied after the lipid nanoparticle containing the drug has been administered to the live subject, and causes controlled release of the drug at the desired site of the body.Type: GrantFiled: June 8, 2016Date of Patent: October 17, 2023Assignee: KING'S COLLEGE LONDONInventors: Maria Thanou, Michael James Lee Wright, Miguel Centelles, Andrew David Miller, Wladyslaw Gedroyc
-
Patent number: 11771703Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGF?2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGF?2-associated diseases, disorders and/or conditions.Type: GrantFiled: March 16, 2018Date of Patent: October 3, 2023Assignee: The Johns Hopkins UniversityInventors: Harry C. Dietz, Joseph Shin
-
Patent number: 11766485Abstract: The present invention relates to a nanoliposome-microbubble conjugate, in which a complex of a Cas9 protein, a guide RNA inhibiting SRD5A2 gene expression and a cationic polymer is encapsulated in a nanoliposome, and to a composition for the amelioration or treatment of hair loss containing the same. Currently, drugs used for the treatment of hair loss cause serious side effects such as loss of libido or erectile dysfunction, and hair loss progresses again when drug treatment is stopped. However, when the nanoliposome-microbubble conjugate of the present invention is used, the expression of SRD5A2 inducing hair loss can be fundamentally suppressed, and the treatment of male hair loss can be performed very effectively.Type: GrantFiled: October 17, 2018Date of Patent: September 26, 2023Assignee: MOOGENE MEDI CO., LTD.Inventors: Jee-Yeon Ryu, Eun-Jeong Won, Han A Reum Lee, Kyeong-Nam Yu
-
Patent number: 11766408Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.Type: GrantFiled: March 4, 2021Date of Patent: September 26, 2023Assignee: The Board of Regents of The University of Texas SystemInventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
-
Patent number: 11759459Abstract: In some embodiments provided herein is a method of treating pain, the method comprising injecting into the subarachnoid space of the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.Type: GrantFiled: October 3, 2022Date of Patent: September 19, 2023Assignee: Pacira Pharmaceuticals, Inc.Inventors: Roy Winston, Kathy Los, Vladimir Kharitonov
-
Patent number: 11739334Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: August 29, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Patent number: 11730825Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: December 21, 2021Date of Patent: August 22, 2023Assignee: TRANSLATE BIO, INC.Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
-
Patent number: 11712419Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.Type: GrantFiled: December 12, 2019Date of Patent: August 1, 2023Assignee: OPKO Pharmaceuticals, LLCInventors: Arturo Santos, Phillip Frost
-
Patent number: 11712407Abstract: The present invention relates to a hybrid-type multi-lamellar nanostructure of an epidermal growth factor and a liposome and a method for manufacturing same. The new type of hybrid-type multi-lamellar nanostructure not only has a high epidermal growth factor encapsulating efficiency, but also can be manufactured through a simple process, such that the same can be easily delivered into a living body or a cell while maintaining a high physiological activity of the epidermal growth factor.Type: GrantFiled: December 30, 2015Date of Patent: August 1, 2023Assignees: CELLTRION, INC., Korea Advanced institute of Science and TechnologyInventors: Yoon Sung Nam, Sung Duk Jo, Bon Il Koo
-
Patent number: 11708575Abstract: This invention provides formulations for use in distributing RNAi molecules targeted to a human GST-? for treating a malignant tumor in a subject. The formulation can include nanoparticles composed of an ionizable lipid, a DSPE lipid, and additional lipids. A drug product can be made by lyophilization of the formulation. This invention further provides methods for ameliorating or treating a malignant tumor by administering a therapeutically effective amount of a formulation containing the RNAi agents.Type: GrantFiled: November 15, 2019Date of Patent: July 25, 2023Assignee: Nitto Denko CorporationInventors: Bharat Majeti, Jean-Pierre Clamme, Li Wang, Roger C. Adami, Wenbin Ying
-
Patent number: 11702483Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.Type: GrantFiled: August 24, 2018Date of Patent: July 18, 2023Assignee: MINERVA BIOTECHNOLOGIES CORPORATIONInventors: Cynthia Bamdad, Benoit Smagghe
-
Patent number: 11690921Abstract: Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.Type: GrantFiled: May 15, 2019Date of Patent: July 4, 2023Assignees: Sangamo Therapeutics, Inc., Life Technologies CorporationInventors: Anthony Conway, Xavier de Mollerat du Jeu, Shikha Mishra
-
Patent number: 11684656Abstract: A new approach for the treatment of a malignant disease is provided. The new method comprises administering a traditional anti-cancer therapy in combination with a DNA or protein vaccine comprising CTLA-4 and PD-1, or a DNA or protein vaccine comprising CTLA-4 and PD-L1.Type: GrantFiled: November 4, 2016Date of Patent: June 27, 2023Assignee: TAIPEI VETERANS GENERAL HOSPITALInventors: Keng-Li Lan, Yi-Sheng Shih, Keng-Hsueh Lan, Sung-Hsin Kuo, Weng-Shiang Chen
-
Patent number: 11672863Abstract: This invention describes compositions comprising at least 75 mg/mL of solubilized otherwise poorly soluble drug in an aqueous environment, wherein the composition further comprises a combination of 3 or more acids. Methods of providing analgesia, anti-pyretic effects or reducing pain in a subject presenting with a pain condition, and methods of reducing administration site irritation, inflammation or a combination thereof in a subject presenting with a pain condition, comprising the steps of administering such compositions and infusion pumps containing such compositions are also described.Type: GrantFiled: May 10, 2018Date of Patent: June 13, 2023Assignee: United Therapeutics CorporationInventors: Michael Laird Hurrey, Drazen Ostovic, Peter Noymer
-
Patent number: 11672814Abstract: The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NGNA are provided for treating or preventing viral infections, such as those causing the common cold.Type: GrantFiled: December 9, 2020Date of Patent: June 13, 2023Assignee: LIFE SCIENCE NUTRITION ASInventors: Jan Remmereit, Dan Edwall, Anders Struksnes
-
Patent number: 11660332Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.Type: GrantFiled: April 27, 2018Date of Patent: May 30, 2023Assignees: The Trustees of the University of Pennsylvania, The Johns Hopkins University, Vanderbilt UniveisilyInventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
-
Patent number: 11655307Abstract: Antibodies and antigen-binding fragments thereof that specifically bind to human DCLK1 protein, hybridomas or other cell lines which express such antibodies and antigen-binding fragments thereof, nucleic acids, vectors, and host cells comprising nucleic acids which encode such antibodies and antigen-binding fragments thereof, and methods of use thereof are disclosed. In at least certain non-limiting embodiments, the antibodies or antigen-binding fragments thereof specifically bind to an epitope within isoform 2 or 4 of DCLK1 protein.Type: GrantFiled: May 30, 2018Date of Patent: May 23, 2023Assignee: The Board of Regents of the University of OklahomaInventors: Courtney W. Houchen, Nathaniel Weygant, Dongfeng Qu, Randal May, Parthasarathy Chandrakesan, William L. Berry
-
Patent number: 11643441Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.Type: GrantFiled: October 21, 2016Date of Patent: May 9, 2023Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sayda Mahgoub Elbashir
-
Patent number: 11633502Abstract: Described herein are liposome-based nanocarriers that selectively target bone marrow, minimize tumor delivery, and maintain high drug concentrations in bone marrow when compared to conventional systemic delivery. The composition of the liposome-based nanocarriers may also be tuned to selectively target lymph nodes and other reticuloendothelial system organs (e.g., spleen, e.g., liver). Also described herein are methods of imaging and mapping the bone marrow and/or other reticuloendothelial system organs using the described liposome-based nanocarriers. These methods provide high resolution non-invasive and quantitative imaging via PET, which offers advantages over conventional imaging/tracking methods. Furthermore, in certain embodiments, the liposome-based carriers are used to stabilize and deliver radioprotectant/free radical scavenger drugs to the bone marrow, thereby protecting the bone marrow from subsequent radiation exposure, thereby limiting the adverse impact of radiation exposure on the individual.Type: GrantFiled: March 7, 2017Date of Patent: April 25, 2023Assignee: Memorial Sloan Kettering Cancer CenterInventors: Naga Vara Kishore Pillarsetty, Steven M. Larson, Sang-gyu Lee
-
Patent number: 11633357Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.Type: GrantFiled: March 1, 2019Date of Patent: April 25, 2023Assignee: ZULI HOLDINGS, LTD.Inventors: Yoram Richter, Yehuda Zelig, Omar Elmalak, Dror Eyal
-
Patent number: 11628132Abstract: Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR—NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells.Type: GrantFiled: January 21, 2020Date of Patent: April 18, 2023Assignee: JUPITER WELLNESS, INC.Inventors: Ofer A. Goren, John McCoy
-
Patent number: 11628227Abstract: Disclosed are formulations for providing a therapeutic bioactive polypeptide to injured tissue. Formulations include mineral coated microparticles wherein a polynucleotide is adsorbed to the mineral layer. Other formulations include a carrier including mineral coated microparticles wherein mineral coated microparticles include a polynucleotide. Also disclosed are methods for sustained delivery of a bioactive polypeptide and methods for treating chronic wounds using a formulation for providing sustained delivery of the bioactive peptide.Type: GrantFiled: July 5, 2018Date of Patent: April 18, 2023Assignee: Wisconsin Alumni Research FoundationInventors: William L. Murphy, Andrew Salim Khalil, Xiaohua Yu
-
Patent number: 11618893Abstract: The present disclosure relates generally to the use of sphingolipid-metabolizing proteins to mitigate or minimize tissue damage resulting from injury or from disease, for example, pulmonary arterial hypertension (PAH) when the sphingolipid-metabolizing protein is delivered via expression from an Anc80 vector.Type: GrantFiled: September 11, 2019Date of Patent: April 4, 2023Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Efrat Eliyahu, Adam Vincek, Anthony Fargnoli, Michael Katz
-
Patent number: 11617796Abstract: The present invention relates to a composition for preventing hair loss and, more specifically, to a compound having a structure in which Minoxidil and a peptide are chemically connected, and to a pharmaceutical composition or cosmetic composition for preventing hair loss or promoting hair growth comprising the compound. The compound having a structure in which Minoxidil and a peptide are chemically connected according to the present invention has not only excellent physiological activity such as hair loss reduction, hair growth promotion or cell growth promotion, but also excellent stability in water, and can therefore be useful as a composition for preventing hair loss and promoting hair growth.Type: GrantFiled: August 4, 2017Date of Patent: April 4, 2023Assignee: Caregen Co., Ltd.Inventors: Yong Ji Chung, Eun Mi Kim
-
Patent number: 11613756Abstract: Disclosed herein are compositions and methods for inhibiting the growth of cells or inducing cell death. The composition capable of inhibiting the growth of cells or inducing cell death comprises a 5?-triphosphate non-linear RNA. The RNA comprises a first stem-loop formed from the complete or partial hybridization of at least 8 nucleotide pairings and may optionally comprise a second stem-loop formed from the complete or partial hybridization of at least 8 nucleotide pairings and a spacer between the first stem-loop and the second stem loop. Methods for inhibiting the growth of cells or inducing cell death comprise contacting cells with the composition or administering the composition to a subject in an amount effective to inhibit the growth of the cells or induce death of the cells.Type: GrantFiled: April 3, 2018Date of Patent: March 28, 2023Assignee: Duke UniversityInventors: Jaewoo Lee, Bruce A. Sullenger, Youngju Lee
-
Patent number: 11607386Abstract: Provided are liposomes that encapsulate adenosine. The liposomes may be formed from sphingomyelin or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) or a combination of sphingomyelin, DMPG, and DMPC. The liposomes encapsulating adenosine may be used to induce cartilage regeneration, treat osteoarthritis, alleviate joint pain, and/or slow, arrest, and/or reverse progressive structural tissue damage associated with osteoarthritis or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and/or synovitis. The liposomes may release adenosine for up to two weeks.Type: GrantFiled: April 3, 2020Date of Patent: March 21, 2023Assignee: New York UniversityInventors: Siddhesh R. Angle, Carmen Corciulo, Bruce N. Cronstein, Jonathan Kaufman
-
Patent number: 11591295Abstract: In an embodiment of the invention, a composition for treating a cell population comprises a medicant. The medicant moiety can be an illudofulvene analog. In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The affinity moiety can be an antibody, an antibody fragment, a receptor protein, a peptidic growth factor, an anti-angiogenic protein, a specific binding peptide, protease cleavable peptide, a glycopeptide, a peptide, a peptidic toxin, a protein toxin and an oligonucleotide. The affinity moiety can be covalently bound to the medicant via a linker.Type: GrantFiled: November 24, 2020Date of Patent: February 28, 2023Assignee: AF CHEMICALS LLCInventor: Michael Kelner
-
Patent number: 11583544Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: GrantFiled: December 24, 2019Date of Patent: February 21, 2023Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka
-
Patent number: 11572389Abstract: Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.Type: GrantFiled: January 26, 2018Date of Patent: February 7, 2023Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: Xinle Cui, Clifford M. Snapper
-
Patent number: 11555177Abstract: Embodiments herein described provide antigen-presenting cell-mimetic scaffolds (APC-MS) and use of such scaffolds to manipulating T-cells. More specifically, the scaffolds are useful for promoting growth, division, differentiation, expansion, proliferation, activity, viability, exhaustion, anergy, quiescence, apoptosis, or death of T-cells in various settings, e.g., in vitro, ex vivo, or in vivo. Embodiments described herein further relate to pharmaceutical compositions, kits, and packages containing such scaffolds. Additional embodiments relate to methods for making the scaffolds, compositions, and kits/packages. Also described herein are methods for using the scaffolds, compositions, and/or kits in the diagnosis or therapy of diseases such as cancers, immunodeficiency disorders, and/or autoimmune disorders.Type: GrantFiled: July 13, 2017Date of Patent: January 17, 2023Assignee: President and Fellows of Harvard CollegeInventors: Alexander Sing Cheung, David J. Mooney
-
Patent number: 11547667Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.Type: GrantFiled: August 19, 2019Date of Patent: January 10, 2023Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ulrich H. von Andrian, Omid C. Farokhzad, Robert S. Langer, Tobias Junt, Elliott Ashley Moseman, Liangfang Zhang, Pamela Basto, Matteo Iannacone, Frank Alexis